Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir

enthalten in: Hepatology Research | 2023

von Uchida, Y. | Imai, Y. | Tsuji, S. | +10

Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation

enthalten in: Hepatology Research | 2022

von Uchida, Y. | Uemura, H. | Tsuji, S. | +9

Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis

enthalten in: Hepatology Research | 2020

von Uchida, Y. | Tsuji, S. | Uemura, H. | +9

Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis

enthalten in: Hepatology Research | 2020

von Uchida, Y. | Inao, M. | Tsuji, S. | +9

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

enthalten in: Hepatology Research | 2020

von Tsuji, S. | Uchida, Y. | Uemura, H. | +9

Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination : A pitfall in antiviral therapy with direct‐acting antivirals

enthalten in: Hepatology Research | 2018

von Kurata, H. | Uchida, Y. | Kouyama, J. | +11